Insulin-Like Growth Factor–Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial

JACC: Heart Failure

Volumn 4, Issue 11, 2016, Pages 860-869

  Gandhi, Parul U ^a,b   Gaggin, Hanna K ^c   Redfield, Margaret M ^d   Chen, Horng H ^d   Stevens, Susanna R ^e   Anstrom, Kevin J ^e   Semigran, Marc J ^c   Liu, Peter ^f   Januzzi, James L ^c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MAYO CLINIC ROCHESTER   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

biomarkers; diastolic function; heart failure with preserved ejection fraction; insulin like growth factor binding protein 7

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; PLACEBO; SILDENAFIL; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIASTOLE; DIASTOLIC DYSFUNCTION; EXERCISE; FEMALE; FUNCTIONAL STATUS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT ATRIUM; HEART RIGHT VENTRICLE PRESSURE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; BLOOD; DAILY LIFE ACTIVITY; DIASTOLIC HEART FAILURE; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACTIVITIES OF DAILY LIVING; AGED; BIOMARKERS; FEMALE; HEART FAILURE; HEART FAILURE, DIASTOLIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXYGEN CONSUMPTION; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SILDENAFIL CITRATE; STROKE VOLUME; VASODILATOR AGENTS;

EID: 84994086937     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.08.002     Document Type: Article

References (25)

1. 1 Bhatia, R.S., Tu, J.V., Lee, D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006), 260–269.
2. 2 Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
3. 3 Nagueh, S.F., Appleton, C.P., Gillebert, T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22 (2009), 107–133.
4. 4 Januzzi, J.L. Jr., Felker, G.M., Surfing the biomarker tsunami at JACC: Heart Failure. J Am Coll Cardiol HF 1 (2013), 213–215.
5. 5 Komajda, M., Carson, P.E., Hetzel, S., et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 4 (2011), 27–35.
6. 6 van Veldhuisen, D.J., Linssen, G.C., Jaarsma, T., et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 61 (2013), 1498–1506.
7. 7 Tschope, C., Kasner, M., Westermann, D., Gaub, R., Poller, W.C., Schultheiss, H.P., The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26 (2005), 2277–2284.
8. 8 Yu, C.M., Sanderson, J.E., Shum, I.O., et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure: higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 17 (1996), 1694–1702.
9. 9 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
10. 10 Barasch, E., Gottdiener, J.S., Aurigemma, G., et al. Association between elevated fibrosis markers and heart failure in the elderly: the Cardiovascular Health Study. Circ Heart Fail 2 (2009), 303–310.
11. 11 Krum, H., Elsik, M., Schneider, H.G., et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 4 (2011), 561–568.
12. 12 de Boer, R.A., Lok, D.J., Jaarsma, T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43 (2011), 60–68.
13. 13 Manzano-Fernandez, S., Mueller, T., Pascual-Figal, D., Truong, Q.A., Januzzi, J.L., Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 107 (2011), 259–267.
14. 14 Chugh, S., Ouzounian, M., Lu, Z., et al. Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics 13 (2013), 2324–2334.
15. 15 Motiwala, S.R., Szymonifka, J., Belcher, A., et al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J Cardiovasc Transl Res 7 (2014), 250–261.
16. 16 Gandhi, P.U., Gaggin, H.K., Sheftel, A.D., et al. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function?. Am J Cardiol 114 (2014), 1543–1549.
17. 17 Redfield, M.M., Chen, H.H., Borlaug, B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309 (2013), 1268–1277.
18. 18 Redfield, M.M., Borlaug, B.A., Lewis, G.D., et al. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail 5 (2012), 653–659.
19. 19 Kashani, K., Al-Khafaji, A., Ardiles, T., et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care, 17, 2013, R25.
20. 20 Severino, V., Alessio, N., Farina, A., et al. Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells. Cell Death Dis, 4, 2013, e911.
21. 21 van Breevoort, D., van Agtmaal, E.L., Dragt, B.S., et al. Proteomic screen identifies IGFBP7 as a novel component of endothelial cell-specific Weibel-Palade bodies. J Proteome Res 11 (2012), 2925–2936.
22. 22 Guo, X.H., Liu, L.X., Zhang, H.Y., et al. Insulin-like growth factor binding protein-related protein 1 contributes to hepatic fibrogenesis. J Dig Dis 15 (2014), 202–210.
23. 23 Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
24. 24 Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
25. 25 Gandhi, P.U., Chow, S.L., Rector, T.S., et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. J Cardiac Fail, 2016 Jun 16 [Epub ahead of print].